Sökning: (WFRF:(van der Lely A. J.)) > Treatment of acrome...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04991naa a2200985 4500 | |
001 | oai:gup.ub.gu.se/251174 | |
003 | SwePub | |
008 | 240528s2000 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2511742 URI |
024 | 7 | a https://doi.org/10.1056/NEJM2000042034216042 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Trainer, P J4 aut |
245 | 1 0 | a Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. |
264 | 1 | c 2000 |
520 | a Patients with acromegaly are currently treated with surgery, radiation therapy, and drugs to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have adverse effects. Pegvisomant is a genetically engineered growth hormone-receptor antagonist that blocks the action of growth hormone.We conducted a 12-week, randomized, double-blind study of three daily doses of pegvisomant (10 mg, 15 mg, and 20 mg) and placebo, given subcutaneously, in 112 patients with acromegaly.The mean (+/-SD) serum concentration of insulin-like growth factor I (IGF-I) decreased from base line by 4.0+/-16.8 percent in the placebo group, 26.7+/-27.9 percent in the group that received 10 mg of pegvisomant per day, 50.1+/-26.7 percent in the group that received 15 mg of pegvisomant per day, and 62.5+/-21.3 percent in the group that received 20 mg of pegvisomant per day (P<0.001 for the comparison of each pegvisomant group with placebo), and the concentrations became normal in 10 percent, 54 percent, 81 percent, and 89 percent of patients, respectively (P<0.001 for each comparison with placebo). Among patients treated with 15 mg or 20 mg of pegvisomant per day, there were significant decreases in ring size, soft-tissue swelling, the degree of excessive perspiration, and fatigue. The score fortotal symptoms and signs of acromegaly decreased significantly in all groups receiving pegvisomant (P< or =0.05). The incidence of adverse effects was similar in all groups.On the basis of these preliminary results, treatment of patients who have acromegaly with a growth hormone-receptor antagonist results in a reduction in serum IGF-I concentrations and in clinical improvement. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng |
653 | a Acromegaly | |
653 | a blood | |
653 | a drug therapy | |
653 | a Adenoma | |
653 | a drug therapy | |
653 | a pathology | |
653 | a Adult | |
653 | a Autoantibodies | |
653 | a blood | |
653 | a Double-Blind Method | |
653 | a Female | |
653 | a Human Growth Hormone | |
653 | a adverse effects | |
653 | a analogs & derivatives | |
653 | a blood | |
653 | a immunology | |
653 | a therapeutic use | |
653 | a Humans | |
653 | a Insulin-Like Growth Factor I | |
653 | a metabolism | |
653 | a Male | |
653 | a Middle Aged | |
653 | a Pituitary Neoplasms | |
653 | a drug therapy | |
653 | a pathology | |
653 | a Receptors | |
653 | a Somatotropin | |
653 | a antagonists & inhibitors | |
700 | 1 | a Drake, W M4 aut |
700 | 1 | a Katznelson, L4 aut |
700 | 1 | a Freda, P U4 aut |
700 | 1 | a Herman-Bonert, V4 aut |
700 | 1 | a van der Lely, A J4 aut |
700 | 1 | a Dimaraki, E V4 aut |
700 | 1 | a Stewart, P M4 aut |
700 | 1 | a Friend, K E4 aut |
700 | 1 | a Vance, M L4 aut |
700 | 1 | a Besser, G M4 aut |
700 | 1 | a Scarlett, J A4 aut |
700 | 1 | a Thorner, M O4 aut |
700 | 1 | a Parkinson, C4 aut |
700 | 1 | a Klibanski, A4 aut |
700 | 1 | a Powell, J S4 aut |
700 | 1 | a Barkan, A L4 aut |
700 | 1 | a Sheppard, M C4 aut |
700 | 1 | a Malsonado, M4 aut |
700 | 1 | a Rose, D R4 aut |
700 | 1 | a Clemmons, D R4 aut |
700 | 1 | a Johannsson, Gudmundur,d 1960u Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism,Institute of Internal Medicine, Dept of Body Composition and Metabolism4 aut0 (Swepub:gu)xjgudn |
700 | 1 | a Bengtsson, B A4 aut |
700 | 1 | a Stavrou, S4 aut |
700 | 1 | a Kleinberg, D L4 aut |
700 | 1 | a Cook, D M4 aut |
700 | 1 | a Phillips, L S4 aut |
700 | 1 | a Bidlingmaier, M4 aut |
700 | 1 | a Strasburger, C J4 aut |
700 | 1 | a Hackett, S4 aut |
700 | 1 | a Zib, K4 aut |
700 | 1 | a Bennett, W F4 aut |
700 | 1 | a Davis, R J4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism4 org |
773 | 0 | t The New England journal of medicineg 342:16, s. 1171-7q 342:16<1171-7x 0028-4793 |
856 | 4 8 | u https://gup.ub.gu.se/publication/251174 |
856 | 4 8 | u https://doi.org/10.1056/NEJM200004203421604 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.